Stayble publishes prospectus in connection with the forthcoming rights issue
Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday, 3 February 2021. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and will be available on their website (www.fi.se). The prospectus is also available on the websites of the Company (www.staybletherapeutics.se), Sedermera Fondkommission (www.sedermera.se) and Nordic Issuing (www.nordic-issuing.se). Teaser and subscription forms will be published on the